Is Baker Hughes Company overvalued?

In our latest published analysis dated 2026-05-20, BKR looks meaningfully overvalued. The price recorded at analysis is USD 66.7 versus a composite fair-value midpoint of USD 53.3 (range USD 40.1–USD 67.6), implying roughly 20.2% downside to the midpoint at that date.

What is BKR's fair value?

Our latest published report, analyzed 2026-05-20, gives BKR a composite fair-value range of USD 40.1–USD 67.6, with a midpoint of USD 53.3. The range is triangulated across multiple valuation models and weighted by reliability for Baker Hughes Company's archetype; it is a dated research output, not a live price.

Should I buy BKR now?

Our latest published rating for BKR, analyzed 2026-05-20, is Reduce with a confidence score of 82/100. Baker Hughes Company looks meaningfully overvalued at the analysis-date price of USD 66.7 versus a fair-value midpoint of USD 53.3. This is research for educational purposes, not personalized investment advice.

What are the biggest risks for BKR?

The top risks our latest published report dated 2026-05-20 flags for Baker Hughes Company are: Cyclical Downcycle; LNG FID Freeze; Margin Contraction.

What is BKR's rating?

Our latest published rating for BKR, analyzed 2026-05-20, is Reduce, with a confidence score of 82/100 and a moat score of 6.5/10. It reflects the composite fair-value range (USD 40.1–USD 67.6) versus the price recorded at analysis (USD 66.7).

What archetype is BKR?

In the latest published report analyzed 2026-05-20, Baker Hughes Company is classified as a cyclical stock. Archetype determines how every downstream parameter — discount rate, terminal growth, deceleration curve, terminal multiple, scenario probability weights, scorecard weights, and which valuation models are prioritized — is calibrated for BKR.

What is BKR's implied growth rate?

Reverse DCF for Baker Hughes Company (BKR) backs out the revenue or earnings growth rate the current share price implies, holding terminal value, margin, and discount-rate assumptions constant.

Is BKR's implied growth realistic?

We compare the implied rate to our own forecast deceleration curve and to the historical five-year actual. When the implied rate exceeds the realistic ceiling, the price is pricing in optimism the business has not yet demonstrated.

What discount rate is used for BKR?

Reverse DCF uses cost of equity (Ke), not WACC, to stay consistent with the EPS-based forward valuation models. Ke is derived from CAPM with adjusted beta; the strict and moderate variants are documented in the assumption ledger.

How does reverse DCF inform a buy or sell call?

When the implied growth rate is below our forecast, the market is underpricing the business; when it is above, the market is overpricing. The reverse-DCF read is one of four lenses that feed the composite fair-value range and the rating band.

BKR reverse DCF: implied growth at the report price

Latest published researchAnalyzed 2026-05-20; report age: stale; sources: unverified. Age and source freshness are disclosed but do not remove the latest published report from discovery or indexing. Prices and valuation figures are the analysis-date snapshot, not a live quote.

Direct answer

Baker Hughes possesses a bifurcated profile. Its traditional OFS segment is subject to intense E&P capital cyclicality, while its IET segment offers a structural growth tailwind via LNG and compression tech. At current valuations, the market is pricing in sustained execution. Fair value range: low $40.1, high $67.6, with mid-point at $53.3.

REVERSE DCF FAQ

BKR reverse dcf questions

Reverse DCF for Baker Hughes Company (BKR) backs out the revenue or earnings growth rate the current share price implies, holding terminal value, margin, and discount-rate assumptions constant.

FAQ

BKR — frequently asked questions

In our latest published analysis dated 2026-05-20, BKR looks meaningfully overvalued. The price recorded at analysis is USD 66.7 versus a composite fair-value midpoint of USD 53.3 (range USD 40.1–USD 67.6), implying roughly 20.2% downside to the midpoint at that date.

Metric	Current	Trigger threshold
Book-to-bill ratio in the IET segment falls below 1.0x.	Monitor	Deterioration versus the report thesis
Consistent downward revisions to forward P/E below the 14x terminal assumption.	Monitor	Deterioration versus the report thesis
Free cash flow conversion drops sharply due to working capital build.	Monitor

Line item	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31	Trend
Revenue	—	$21.16B	$25.51B+20.6%	$27.83B+9.1%	$27.73B-0.4%	+7.0%
Gross profit	—	$4.40B	$5.90B	$6.48B	$6.54B	+10.4%
Operating income	—	$1.89B	$2.64B	$3.38B	$3.56B	+17.1%
Net income	—	$-601.0M	$1.94B	$2.98B+53.6%	$2.59B-13.1%	—
EPS (diluted)	$-0.27	$-0.61	$1.91	$2.98	$2.60	—
EBITDA	—	$1.34B	$3.96B	$4.60B	$4.29B	+33.9%
R&D	—	—	$651.0M	$643.0M	$600.0M	-2.0%
SG&A	—	$2.51B	$2.61B	$2.46B	$2.39B	-1.2%

BKR reverse dcf questions

BKR — frequently asked questions

BKR Baker Hughes Company fair value $40–$68

§1 Executive summary

Names readers of BKR also follow

§2 Bear case

Cyclical Downcycle

LNG FID Freeze

Margin Contraction

§3 Financial history

Income statement — last six periods

Quality scores

Numbers analysis

Read the full analysis — 11 more sections.